Drug Topics
JUNE 10, 2025
Enflonsia provides an important new preventive option to help protect healthy and at-risk infants born during or entering their first RSV season with the same dose regardless of weight,” Dean Y Li, president of Merck Research Laboratories, said in a release.
Drug Topics
JULY 10, 2025
Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community,” Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories, said in a release.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 16, 2025
Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
Pharmaceutical Technology
OCTOBER 14, 2022
The mRNA-4157/V940 has been designed to stimulate an immune response by producing T-cell responses depending on the mutational signature of a patient's tumour.
European Pharmaceutical Review
APRIL 17, 2023
I look forward to working with the Prometheus team to establish a new paradigm of precision treatment for immune diseases,” commented Dr Dean Y Li, President of Merck Research Laboratories. Prometheus is a clinical-stage biotechnology company. “I
The People's Pharmacy
JUNE 15, 2023
Commins sees patients in the UNC allergy clinic and maintains an active research laboratory. His primary research and clinical interest is alpha-gal syndrome. Patients in the allergy clinic often have difficult to diagnose food allergies or allergic reactions. Photo by Chris Polydoroff.
Pharmaceutical Technology
JUNE 23, 2022
According to findings from a pivotal study, a four-dose paediatric regimen of Vaxneuvance induced immune responses non-inferior to the presently available 13-valent pneumococcal conjugate vaccine (PCV13) for the 13 shared serotypes.
Expert insights. Personalized for you.
Let's personalize your content